FDA approves Celltrion’s biosimilars for various indications
This approval covers all indications of the reference products and the biosimilars are anticipated to be available by June 2025 in the country as per the settlement agreement
Swiss biopharmaceutical company Relief Therapeutics has confirmed the termination of discussions with the US-based clinical-stage biotechnology company Renexxion regarding a potential merger.
Investors for the funding round include Johnson & Johnson Innovation, Deerfield Management, Catalio Capital Management, Braidwell, the Retinal Degeneration Fund, and GV. The company is dedicated to advancing